TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Return on equity 2023–2025
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-50.6%FY2025 · since FY2023: -110.6% → -50.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -50.6% | +42.6 pp |
| FY2024 | -93.2% | +17.4 pp |
| FY2023 | -110.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More TNXP financial trends
TNXP RevenueTNXP Net incomeTNXP Net marginTNXP Gross profitTNXP Gross marginTNXP Operating incomeTNXP Operating marginTNXP Operating cash flowTNXP Free cash flowTNXP Capital expendituresTNXP Stock buybacksTNXP Dividends paidTNXP Total assetsTNXP Total liabilitiesTNXP Shareholders’ equityTNXP overview →